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Abstract
The current classification of human sporadic prion diseases recognizes six major phenotypic
subtypes with distinctive clinicopathological features, which largely correlate at the molecular
level with the genotype at the polymorphic codon 129 (methionine, M, or valine, V) in the prion
protein gene and with the size of the protease-resistant core of the abnormal prion protein, PrPSc
(i.e. type 1 migrating at 21 kDa and type 2 at 19 kDa). We previously demonstrated that PrPSc
typing by Western blotting is a reliable means of strain typing and disease classification.
Limitations of this approach, however, particularly in the interlaboratory setting, are the
association of PrPSc types 1 or 2 with more than one clinicopathological phenotype, which
precludes definitive case classification if not supported by further analysis, and the difficulty of
fully recognizing cases with mixed phenotypic features. In this study, we tested the inter-rater
reliability of disease classification based only on histopathological criteria. Slides from 21 cases
covering the whole phenotypic spectrum of human sporadic prion diseases, and also including two
cases of variant Creutzfeldt–Jakob disease (CJD), were distributed blindly to 13 assessors for
classification according to given instructions. The results showed good-to-excellent agreement
between assessors in the classification of cases. In particular, there was full agreement (100 %) for
the two most common sporadic CJD subtypes and variant CJD, and very high concordance in
general for all pure phenotypes and the most common subtype with mixed phenotypic features.
The present data fully support the basis for the current classification of sporadic human prion
diseases and indicate that, besides molecular PrPSc typing, histopathological analysis permits
reliable disease classification with high interlaboratory accuracy.
Introduction
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are rare and fatal
neurodegenerative disorders characterized by tissue deposition of a misfolded isoform of the
cellular prion protein (PrPC), commonly referred to as PrPSc [34].
Prion diseases in humans can be sporadic, familial, or acquired. The sporadic form, by far
the most common, comprises a broad spectrum of clinicopathological variants that show
heterogeneity in disease duration, symptomatology, and type or regional distribution of brain
lesions [30]. Prion strains, defined by their distinct phenotypes upon serial transmission to
syngenic animals, are believed to be the main cause of this phenotypic diversity [1]. In
addition, the host variability in the gene encoding PrPC (PRNP), as determined in humans by
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polymorphisms or mutations, has also been recognized to be a source of disease
heterogeneity [6, 8, 9].
Although uncertainties remain regarding the molecular basis of prion strains, circumstantial
evidence suggests that the strain phenotypes are enciphered in distinct tertiary or even
quaternary structures of PrPSc (reviewed in [1]). In human prion disease, different PrPSc
profiles or types characterized by distinctive physicochemical properties such as size after
protease treatment, degree of protease resistance, and glycoform ratio have been shown to
correlate with the phenotypic heterogeneity of the disease and, to some extent, with the
strain properties after transmission [5, 7, 18, 20–22, 25–27, 32, 33, 36, 39].
In sporadic human TSEs, for example, the combination of two main PrPSc types commonly
referred to as type 1 and type 2, showing distinct sizes of the unglycosylated protease-
resistant C-terminal core (21 vs. 19 kDa), and the genotype at the PRNP polymorphic codon
129, encoding for either methionine (M) or valine (V), is significantly related to the
phenotypic variability of the disease, and has provided a molecular basis for its classification
[25, 28]. The latter currently includes six major phenotypic variants, each resulting from a
specific codon 129 genotype/PrPSc type (1, 2, or 1 + 2) combination, with only three
exceptions: MM1 and MV1 cases appear phenotypically indistinguishable and have been
merged into one subtype (MM/MV 1), whereas the MM2 and MV2 combinations are both
associated with two subtypes with distinctive histopathological features. The MM2 subtype
showing confluent vacuoles and a predominant cortical pathology has been designated
MM2-cortical (MM 2C), whereas that characterized by prominent atrophy of thalamic and
inferior olivary nuclei has been defined as either the sporadic form of fatal insomnia (sFI) or
as sCJD MM2-thalamic (MM 2T) [24, 28]. Similarly, the most common MV2 subtype with
cerebellar amyloid plaques of the kuru type has been designated MV 2-kuru (MV 2K),
whereas the rare MV2 cases with cortical confluent vacuoles have been denoted MV2-
cortical (MV 2C).
The six sporadic prion disease subtypes differ from each other in several clinicopathological
and biochemical features, and five of them (MM/MV1, VV2, VV1, MM/MV 2C, and MM
2T) appear to propagate in animal models as different prion strains [2, 14–17, 20, 26].
Interestingly, some of the six sporadic prion disease subtypes have also been found to co-
occur in the same brain with variable frequency, indicating the possibility that prion strain
co-occurrence (i.e. generating distinct disease phenotypes upon transmission to susceptible
syngenic animals) may also take place in sCJD, as has been suggested for scrapie [4, 5, 10,
28, 31, 35].
Variant CJD (vCJD or MM 2V) represents an additional very distinctive CJD phenotype. It
originated from a bovine prion strain [3, 38], and is characterized by a type 2 PrPSc form
that differs from the type 2 found in sCJD due to a relatively high representation of the
diglycosylated PrPSc glycoform [7, 23].
Given the biological and phenotypic heterogeneity of prion diseases, the correct
identification or “typing” of the prion strain/s associated with each case of human TSE has
obvious implications for disease diagnosis, epidemiologic surveillance, and future
therapeutics. Transmission studies are extremely expensive, time-consuming, and only give
information about the inoculum used, which is not necessarily representative of the whole
affected brain. Either molecular or histopathological data (or both) may, therefore, provide
reliable surrogate markers for strain typing in humans.
Analysis of the physicochemical properties of PrPSc (i.e. PrPSc “typing”) has already proven
to be a reliable means of strain typing and performing molecular classification of CJD [29].
Limitations of this approach, however, particularly in the interlaboratory setting, are the
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association of one PrPSc type with more than one CJD phenotype, which precludes the
ultimate case classification if not supported by further analysis (e.g. PrPSc type 1 in MM1 or
VV1 types or type 2 in MM 2C or MM 2T types), and the difficulty involved in fully
recognizing the sCJD cases with mixed phenotypic features, in particular when one of the
co-occurring PrPSc types 1 and 2 expresses itself only focally, as in some MM 1+2C cases,
or when the co-occurring sCJD phenotypes are associated with the same PrPSc type (e.g.
MV 2K+C or MM 2T+C) [29, 31]. Furthermore, PrPSc typing cannot be performed in cases
lacking fresh or frozen brain tissue. As it is based on the recognition of distinctive
histopathological features, CJD “histotyping” may not suffer from the limitations listed
above. In particular, CJD histotyping has been recently reported to perform better than PrPSc
typing in recognizing sCJD subtypes with mixed phenotypical features, especially for MM
or MV subjects [12, 31].
The full validation of CJD histotyping requires the standardization and harmonization of
practice among laboratories. To achieve this aim, a collaborative study among seven
laboratories involved in TSE surveillance in several European countries and the USA was
set up to compare the classifications assigned and to assess their reproducibility among
different assessors. Laboratories were sent selected sections from cases of sCJD and vCJD
with detailed protocols to be followed in determining the histotype according to the
classification originally proposed by Parchi et al. [28], which was recently updated with the
inclusion of categories for mixed subtypes [31].
Materials and methods
Case and tissue selection
The study was based on tissue samples from subjects affected by various subtypes of human
prion disease, including the whole spectrum of currently characterized human prion strains
[30]. All cases were selected from a larger pool of pathological material based on the
following essential criteria: (1) availability of all necessary brain structures (see below); (2)
inclusion of all known sporadic TSE subtypes according to the updated classification of
Parchi et al. [31] as well as vCJD; and (3) absence of additional significant pathological
comorbidity, such as “intermediate” or “high” Alzheimer’s disease neuropathological
changes [19], cerebral haemorrhages or infarcts, or a known history of neurological
disorders other than prion disease. PRNP genetics and PrPSc typing had been performed in
all selected cases as described previously [10, 31]. PrPSc typing, in particular, was
performed in each case in at least six brain samples (frontal, temporal, parietal, and occipital
cortices, thalamus, and cerebellum). Local ethical committee approval (Medical Ethics
Committee of the Ludwig Maximilians University, Munich) was obtained for the study of
autopsy material, with written informed consent for research use provided by the patients
during life or by their next of kin after death.
A total of 21 cases were included. Two “atypical” CJD cases (i.e. not fitting any of the
subtypes defined by the current CJD classification) were also added to the series. The total
number and anatomical representation of the sections included in the study were chosen by
the reference group (PP, AG, and HK). The two major aims were on the one hand to keep
the number of slides to a minimum and on the other to select all brain regions that highlight
the distinctive features of each TSE subtype [11, 30, 31].
All selected cases displayed histopathological lesions and PrP-immunoreactive deposits.
Two sets of 4 μm thick sections were produced. Each set contained haematoxylin and eosin
(H&E) stained sections from seven brain areas (frontal and occipital cortices, hippocampus,
striatum, thalamus, medulla, and cerebellum) of the 21 cases, as well as sections stained for
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PrP by immunohistochemistry from the frontal and occipital cortices, hippocampus, and
cerebellum of all cases. All sections were stained using the same methodology in one
laboratory (LMU, München). Specimens were sent blindly with a combined letter and
numerical code together with the operative instructions (see below).
Immunohistochemistry
In brief, after rehydration, the sections were autoclaved in citrate buffer and pretreated with
98 % formic acid for 60 min. Subsequently, the sections were incubated overnight at 4 °C
with a monoclonal primary antibody directed against PrP (mab L42, a gift from Martin
Groschup [37], diluted 1:50). The reaction product was visualized using the I View DAB
detection system (Ventana/Roche, Mannheim, Germany) with the use of DAB as the
chromogen.
Construction of assessment instructions and reference assessment of the selected
material
Members of the reference group (PP, AG, HK) prepared a draft of the assessment
instructions, including a detailed description of the typical histopathological features as well
as the major exclusion criteria for each CJD type (Table 1), a diagnostic flow chart to be
followed during the assessment (Fig. 1), photographs and definitions of the pathology to be
evaluated (Fig. 2; Table 2), and a standardized data sheet (Table 3). The latter aimed to
collect information on the dominant vacuole size, on the main pattern of PrP deposition, and
on whether or not kuru-type or florid amyloid plaques were seen. In addition, five specific
questions concerning the distribution and severity of histopathological lesions in specific
neuroanatomical structures were included (Table 3). Finally, an alternative nomenclature,
more suitable for a histopathological diagnosis performed in the absence of molecular data,
was proposed for each of the sporadic disease variants or subtypes (Table 4).
Assessors were then invited to a joint meeting to discuss the document drafts and
simultaneously assess some exemplary cases using a multi-headed microscope.
The documents were then refined based on the most significant suggestions that emerged
during the meeting, and a final version of each document (Tables 1, 2, 3, 4; Figs. 1, 2) was
prepared by the reference group to be circulated among the participants.
Instructions to raters
All raters were supplied with the written directives on the criteria to define each CJD type,
the definition of the lesions to be assessed, the diagnostic flow-chart to follow, and the
standardized assessment sheet. Raters were requested to fill in the data sheet and assign a
CJD type diagnosis based on the criteria summarized in Table 1 and the guidance given by
the diagnostic flow-chart (Fig. 1).
Joint assessment by the reference group
Following the individual assessment phase, the reference group convened a meeting to
jointly analyze the data recorded in the assessment sheets by each evaluator. Inconsistencies
in these observations were discussed and pitfalls were sought. In particular, the consistency
between the actual observations made by the assessor concerning the type and distribution of
histopathological lesions (upper part of the assessment sheet) and the final CJD type-specific
diagnosis were carefully evaluated. In other words, the accurate application of diagnostic
criteria by each assessor was double-checked. Finally, when there were significant
discrepancies among the assessors, the stained sections were re-evaluated under the multi-
headed microscope.
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Results
Reference group joint assessment
One of the 21 selected cases gave rise to a highly significant inter-rater discrepancy in the
assessment. Originally selected as a case of sCJD MV 2K, under the joint reassessment the
case was re-classified as MV 2K+C because of the recognition of a tiny area in the cerebral
cortex showing large confluent vacuoles and a perivacuolar pattern of PrP deposition.
The joint re-analyses also identified two assessments in which there was an obvious
inconsistency between the observed lesions (i.e. those described in the upper part of the
assessment sheet) and the final chosen TSE histotype. The first concerned the atypical case
showing amyloid plaques and plaque-like PrP deposition in both cortical and cerebellar
white matter. One assessor correctly identified this case as an atypical MM1 case with white
matter amyloid plaques as described by Kobayashi et al. [13], but then typed it as MM/
MV1. The second inconsistency concerned a typical VV2 case. The assessor correctly
identified all of the distinctive features of the VV2 sCJD histotype and did not report any
atypical features, but then crossed the box “atypical case”. Given the obviousness of these
discrepancies, the final diagnosis was changed accordingly for both of these assessments.
Agreement of different raters
Table 5 shows how the 21 cases were “histotyped” by the 13 assessors. Apart from the case
which was re-assessed and re-typed by the reference group, the inter-rater histotyping
agreement was high overall, ranging from 69 to 100 %. All of the assessors were in full
agreement regarding the assigned histotype in nine cases, and showed very strong agreement
(i.e. only one or two divergent assessments) in six additional cases. Overall, the agreement
was strongest (full agreement) for the two most common sCJD histotypes (i.e. MM/MV1
and VV2) and vCJD, very high for the pure phenotypes MV 2K, MM 2T, and MM 2C as
well as the mixed MM/MV 1+2C subtype, whereas the pure phenotype VV1, the mixed MV
2K+C subtype and the “atypical” cases shared the lowest degree of diagnostic concordance.
Taken together, 11 out of the 13 raters assessed 86–100 % of the cases correctly.
Analyses of divergent assessments
The analyses of the histotype assessments, which were at variance with those of the
reference group, showed that the discrepant diagnosis was generated either by the incorrect
application of diagnostic criteria or by obvious misjudgement in about 30 % of cases. For
example, in three instances, MM 2C cases were typed as MV 2K despite no kuru-type
amyloid plaques being seen; in another one, the rater typed an atypical case showing
amyloid plaques in the white matter as MV 2K despite the fact that no plaque-like deposits
were detected in the cerebellar granular layer, and two assessors typed a MM 2C case as
MM 1+2C despite no synaptic deposits being seen in the molecular layer of the cerebellum.
Furthermore, in four instances, the two atypical cases were typed either as VV1 or as MM/
MV1 despite the presence of plaque-like deposits, which was given as an exclusion criterion
for both the VV1 and MM/ MV1 histotypes.
There were only two significant sources of divergent assessment that were unrelated to
incorrect application of the diagnostic criteria. The first concerned the recognition of MM
2C features co-occurring with either MM/MV1 or MV 2K, especially when they were focal
and limited to one area in one slide, whereas the second pertained to the distinction between
the MM/MV1 and the VV1 histotypes. Finally, additional minor sources of incorrect
assessment were the lack of recognition of the cerebellar amyloid plaques of the kuru type in
two cases by one rater, and the lack of recognition of the rarest phenotypes (the MM 2C,
MM 2T, and VV1 variants were typed as atypical cases once each) by three raters.
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Analyses of the prion-related pathology assessment
The analyses of the data sheet (Table 3) including the assessment of the prion-related
histopathology provided additional relevant information.
Vacuole size—This morphological feature is relevant to distinguish between MM/MV1
and VV1, and it represents, above all, one of the distinctive histological markers for the MM
2C type. As far as the first differential diagnosis was concerned, the presence of medium-
sized vacuoles in the cerebral cortex was recognized in 25 out of 26 assessments in the VV1
cases, and in 10 out of 26 assessments in the MM/MV1 cases. More significantly, while 22
out of 26 evaluations detected medium-sized vacuoles in the striatum of VV1, none of the
assessors saw the same type of vacuoles in the striatum of MM/MV1 cases. Furthermore,
while all participants identified the relative sparing of cerebellum compared to the frontal
cortex in the VV1 cases, none of them detected the same characteristic in the MM/MV1
cases. Finally, recognition of large confluent vacuoles was significantly associated with the
MM/ MV 2C type (either pure or mixed) with 86.3 % specificity and 96.2 % sensitivity (the
specificity increased to 97 % when the two vCJD cases were excluded from the analyses).
Kuru-type plaques in the cerebellum—These were only detected in MV 2K or MV
2K+C (100 % specificity), although one assessor did not identify the plaques in two cases
(96.2 % sensitivity).
Florid-type plaques—These were seen only in vCJD by all evaluators (100 % specificity
and sensitivity).
Pattern of PrP deposition (IHC)—As expected, none of the recognized patterns of PrP
deposition (i.e. synaptic, coarse/perivacuolar, plaque-like, and perineuronal) were
specifically associated with a single histotype. Furthermore, the analyses of the inter-rater
assessment of PrP deposition revealed significant disagreement among assessors in the
definition of cerebellar and, to a lesser extent, cortical deposits in MM 2C cases. Indeed,
while 100 % of evaluations recognized coarse and perivacuolar protein deposits in the
cerebral cortex, in agreement with previous reference descriptions of this rare subtype [28,
31], some (49 %) also detected plaque-like deposits. Even more strikingly, cerebellar PrP
deposits in MM 2C cases were more frequently described as plaque-like than as coarse or
perivacuolar (85 vs. 36 %).
Nevertheless, when the analysis was restricted to specific anatomical regions, the coarse/
perivacuolar pattern in the cerebral cortex was significantly associated with the MM/MV 2C
type (either pure or mixed) with 91 % specificity, and the plaque-like pattern in the granular
layer of cerebellum with both VV2 and MV 2K types (93 % specificity among sCJD
subtypes).
Similarly, the perineuronal pattern of PrP deposition was significantly associated with both
the VV2 and MV 2K subtypes (98 % sensitivity and 92 % specificity among sCJD
subtypes). Finally, the synaptic pattern of PrP deposition only appeared useful as a negative
marker; indeed, among cases lacking amyloid plaques, the absence of this pattern in the
cerebellum strongly indicated either the MM 2C or the MM 2T subtype.
Analyzing the answers given by the assessors to the five questions included in the data sheet
(Table 3) gave the following results:
1. The recognition of a clear-cut laminar pattern in the cerebral cortex (Fig. 3) was
significantly correlated with either the VV2 or the MV 2K subtype (96 %
sensitivity and 94 % specificity).
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2. The relative sparing of the cerebellum compared to the frontal cortex distinguished
the MM 2C, MM 2T, and VV1 groups (Fig. 3) from the other CJD subtypes (93 %
sensitivity and 86 % specificity).
3. The coexistence of moderate to severe thalamic and olivary atrophy (Fig. 3) was a
strong diagnostic marker for the MM 2T subtype (100 % sensitivity and 99 %
specificity).
Discussion
In the present study we tested, for the first time, the inter-rater reliability of
histopathological criteria aimed at distinguishing among sporadic human prion disease
subtypes as well as vCJD. Most of the neuropathologists responsible for human TSE
diagnosis in Europe and the USA were involved in this study. By showing an overall strong
agreement among the raters, the results obtained not only fully support the current
classification of human prion disease, but also demonstrate that neuropathological
examination alone allows reliable classification and strain typing in the absolute majority of
cases, with obvious implications for current diagnostic practice and epidemiologic studies.
Results were particularly excellent for vCJD, the three most common pure sCJD subtypes
(i.e. MM/MV1, VV2, and MV 2K), and MM 2T, a rare but very distinctive disease subtype,
also known as sFI. Notably, four out of five of these human sporadic TSE variants have
been shown to generate distinct prion strains upon transmission to experimental animals,
which points further to the strain phenomenon being the main determinant of phenotypic
variability in human prion disease [2, 14–17, 20, 26]. Among the pure and strain-specific
sCJD subtypes, results were less satisfactory only for the VV1 group, one of the rarest sCJD
variants. Nevertheless, the results of the present study indicate that the diagnostic accuracy
of this sCJD type, and its distinction from the MM/MV 1 variant in particular, can be further
improved by more strongly emphasizing the combined criteria of (1) the presence of
medium-sized vacuoles in the striatum and (2) the relative sparing of cerebellum compared
to the frontal cortex. Indeed, by retrospectively applying only these two features as inclusion
criteria, we calculated that there was 89 % assessor agreement in the distinction between the
two subtypes. Furthermore, it must be also considered here that codon 129 genotyping,
which is often performed on blood samples collected in vitam, may also help to corroborate
the correct typing of VV1 cases, even in the absence of frozen tissue.
The most significant source of disagreement among raters was, as expected, the recognition
of the co-occurrence of phenotypic features of two subtypes when one of the two is only
focally expressed. This difficulty was especially evident in the MM/MV 2K+C group, likely
because the coarse/perivacuolar pattern (“2C” phenotype) is less distinguishable from the
plaque-like pattern (“2K” phenotype) than from the synaptic pattern (MM/MV1 phenotype).
The results obtained, showing strong agreement in three out of four cases, are, nevertheless,
encouraging and significant, given that histopathological examination is to date the only way
to recognize mixed phenotypes associated with the same (or similar) PrPSc type (i.e. 2K+C).
Furthermore, it should be borne in mind that in order to reduce the complexity and the cost
of the diagnostic protocol in this study, we kept the number of slides to a minimum, while
the chance of recognizing focal phenotypic features is known to increase—at least to a
certain degree—with the amount of tissue examined. Based on the present results it is
therefore recommended that a minimum of four samples from the cerebral cortex (one for
each lobe) should be examined histopathologically, as recently proposed by Parchi et al.
[31]. Similarly, it is recommended that at least two distinct samples of cerebellum—possibly
including the vermis—should be examined, since this will increase the likelihood of the
amyloid kuru-type plaques being recognized, even when they are scanty.
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The analyses of the assessments of PrP immunostaining indicate that none of the previously
defined patterns of PrP deposition are fully specific to one histotype, although each of the
three major PrP staining patterns (i.e. synaptic, coarse/perivacuolar, and plaque-like)
strongly characterizes some of the histotypes either positively (i.e. it is always present) or
negatively (i.e. it is always absent). As a consequence, the present results validate PrP
staining as a reliable source of exclusion diagnostic criteria for some disease subtypes. The
most significant examples of such exclusion criteria include the presence of either coarse/
perivacuolar or plaque-like deposits in the grey matter of MM/MV1, VV1, or MM 2T, the
absence of plaque-like deposits in VV2, the absence of coarse or perivacuolar deposits in
MM/MV 2C, the absence of PrP-positive amyloid plaques in the granular layer of
cerebellum in MV 2K, and the presence of a synaptic type of staining in the molecular layer
of cerebellum in MM 2C.
Similarly, the assessment of the regional distribution of lesions confirmed that some
patterns, although not totally specific to one histotype, constitute reliable supporting
diagnostic criteria for some disease subtypes. These include, in order of importance, the
moderate to severe thalamic and olivary atrophy seen in MM 2T (Fig. 3), the relative sparing
of cerebellum compared to the cerebral cortex seen in VV1 (Fig. 3) and MM 2C, and the
laminar intracortical distribution of spongiform change seen in VV2 (Fig. 3) or MV 2K.
Finally, it is also important to underline that all 13 assessors from the seven laboratories
involved in CJD surveillance worldwide correctly identified the two vCJD cases and
distinguished them from all sCJD variants and atypical cases without the need for PrPSc
typing. In practical terms, this is also a significant result for human CJD surveillance in
Europe and USA.
In conclusion, this study validates “histotyping” as a reliable means of human prion disease
classification and provides detailed instructions for histopathological typing that can be used
as a reference for future epidemiological studies. When combined with those previously
obtained on PrPSc typing [29], the present results indicate that both molecular (i.e. PrPSc
typing and codon 129 genotyping) and histopathological analyses are reliable and powerful
approaches for human prion disease classification and strain typing. They both guarantee an
extremely high interlaboratory accuracy even when applied individually, although the
combination of the two approaches, when feasible, remains the gold standard for the
diagnosis and classification of human prion disease.
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Fig. 1.
Recommended diagnostic flowchart for diagnosing human sporadic prion disease histotypes
and vCJD
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Fig. 2.
Distinctive histopathological features of sporadic human prion disease subtypes. a Typical
spongiform change characterized by small, fine, microvacuoles (H&E stain, sCJD MM1,
cerebral cortex); b spongiform change characterized by medium-sized vacuoles (H&E stain,
sCJD VV1, cerebral cortex); c spongiform change characterized by relatively large
confluent vacuoles (H&E stain, sCJD MM 2C cerebral cortex); d unicentric amyloid plaque
of the kuru type (H&E stain, sCJD MV 2K, cerebellum); e, f florid plaques in the cerebral
cortex (PAS stain and PrP IHC, vCJD, cerebral cortex); g synaptic pattern of PrP deposition
in the cerebellum of sCJD MM1. A delicate diffuse staining is seen in the molecular layer,
while the cerebellar glomeruli are stained in the granular cell layers. h Perivacuolar and i
coarse PrPSc staining as typically seen in MM 2C and MM/MV 1+2C mixed sCJD cases.
The cerebellum in MM 2C is either PrP negative or shows a focal patchy/coarse staining (j).
k Plaque-like PrP deposits in the granular and molecular layers of the cerebellum in MV 2K.
l Smaller plaque-like PrP deposits in the granular and molecular layers of the cerebellum in
sCJD VV2. These plaque-like deposits are not visible in routine H&E or PAS-stained
sections. m Perineuronal PrPSc staining in the deep cortical layers of sCJD VV2. All
pictures in the panel have the same magnification (×200), except for d (×400) and g (×100)
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Fig. 3.
Distinctive regional distribution of histopathological changes in sCJD histotypes MM 2T,
VV1, and VV2. Severe neuronal loss and gliosis in the medial thalamic (a) and inferior
olivary nuclei (b) and relative sparing of anterior striatum (c) in sCJD MM 2T. Moderate to
severe spongiform change (small to medium-sized vacuoles), gliosis, and neuronal loss in
the cerebral cortex (d) and anterior striatum (e), and relative sparing of the cerebellum (f) in
sCJD VV1; laminar distribution of spongiform change, with relative sparing of superficial
(g) compared to the deep (h) layers in the cerebral neocortex of sCJD VV2. Severe
spongiform change in the CA1/subiculum areas of the hippocampus (i) despite the virtually
complete sparing of the occipital cortex (j) in a typical VV2 case with a relative short
duration (five months). All pictures in the panel have the same magnification (×100) except
for a and b (×200)
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Table 1
Diagnostic criteria for pure and mixed human TSE histotypes
Histotype Typical features Major criteria for exclusion
Pure phenotypes
 MM/MV 1 Spongiform change characterized by small vacuoles with predominant
corticostriatal-thalamic and cerebellar involvementa
Relative sparing of hippocampus compared to occipital cortexb
Absence of a definite/clear-cut laminar pattern (i.e. predominant involvement
of deep layers) of spongiform change and PrP deposition in the cerebral
cortexc
Synaptic pattern of PrP deposition
Clusters of large, confluent vacuoles in
the grey matter
Coarse or perivacuolar PrP deposition in
the grey matter
PrP plaque-like deposition
PrP-positive amyloid plaques
 VV2 Spongiform change characterized by small and medium-sized vacuoles
Significant spongiform change in subcortical grey matter which is often more
severe in striatum than in cerebral neocortex
More severe spongiform change in the hippocampal CA1 and subiculum than
in the occipital cortex
Definite laminar pattern (i.e. predominant involvement of deep layers) of
spongiform change and PrP deposition in at least one specimen from the
cerebral cortex
Plaque-like PrP deposition (best seen in cerebellar granular layer and white
matter), usually associated with a perineuronal pattern in deep cortical layers
and CA4
Significant cerebellar atrophy (particularly involving the granule cell layer) in
comparison to that of occipital cortex
Clusters of large, confluent vacuoles
associated with perivacuolar/coarse PrP
deposition in the grey matter
Typical fully formed PrP-positive
amyloid plaques of the kuru-type or
florid plaques in the cerebellum or other
areas
Absence of plaque-like PrP deposition
 MV 2K Widespread cortical and subcortical pathology with plaque-like PrP
deposition and amyloid plaques of kuru type mainly localized in the cerebellar
granular layer
Clusters of large confluent vacuoles
associated to perivacuolar PrP
deposition in the grey matter
Absence of PrP-positive amyloid
plaques of the kuru type in the
cerebellum
Amyloid plaques of the florid type in
the cerebral cortex
 MM/MV 2C Corticostriatal distribution of pathology with relative sparing of brainstem and
cerebellum
Spongiform change mainly comprising grape-like clusters of relatively large
confluent vacuoles
PrP-positive amyloid plaques
Synaptic-type PrP staining in the
molecular layer of cerebellum
 MM 2T (sFI) Moderate to severe selective atrophy of thalamic nuclei (i.e. anterior,
dorsomedial, and pulvinar) in the absence of definite spongiform change in
the same regions and not associated with severe cortical atrophy
Moderate to severe selective atrophy of inferior olivary nuclei
Absence of definite spongiform change in the cerebellum
Relative sparing of striatum compared to the thalamus
Definite PrP plaque-like or perivacuolar
deposition
PrP-positive amyloid plaques
 VV1 Corticostriatal distribution of pathology with relative sparing of cerebellum
compared to the cerebral cortex
Spongiform change comprising medium-sized vacuoles
Synaptic PrP deposition (usually faint)
Presence of (often) ballooned neurons in the most severely affected areas of
the cerebral cortex
Clusters of large vacuoles in the grey
matter
Definite coarse or perivacuolar PrP
deposition in the grey matter
Plaque-like PrP deposition in the grey
matter
PrP-positive amyloid plaques
The cerebellum is more involved (i.e.
shows more significant pathological
changes) than the frontal cortex
 vCJD (MM 2V) Multiple florid plaques in the cerebral cortex (all lobes) and cerebellar cortex
Spongiform encephalopathy most marked in the caudate nucleus and putamen
Severe neuronal loss and gliosis in the pulvinar of the thalamus
PrP-positive florid plaques, small cluster plaques and amorphous pericellular
and pericapillary deposits
Absence of florid plaques in routinely
stained sections
Lack of PrP-positive florid plaques,
small cluster plaques and amorphous
pericellular and pericapillary deposits
Mixed phenotypes
 MM/MV 1+2C Fits most criteria for MM/MV 1, but:
Also shows clusters of large vacuoles associated with perivacuolar and coarse
PrP deposition in the grey matter (most commonly in cerebral cortex or
thalamus)
or
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Histotype Typical features Major criteria for exclusion
Fits most criteria for MM 2C, but also shows synaptic-type PrP staining in the
molecular layer of the cerebellum
 MV 2K+C Fits most criteria for MV 2K, but also shows clusters of large vacuoles
associated with perivacuolar and coarse PrP deposition in the grey matter
(most commonly in cerebral cortex or thalamus)
 Atypical Any case which does not fit the criteria for the pure or mixed phenotypes
outlined above
a
The vacuolation largely disappears and is replaced by status spongiosus in cases with long duration and severe atrophy and gliosis
b
In cases with long duration and severe cortical atrophy and astrogliosis, this assessment should not be based on the degree of spongiform change
but rather on the extent of neuronal loss and astrogliosis
cAn apparent predominant PrP deposition in the deep cortical layers may be seen in cases with long duration and severe cortical atrophy and
astrogliosis
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Table 2
Definition of “diagnostic” lesions (see also Fig. 1)
Spongiform change PrP+ amyloid deposits Other PrP deposits
Small vacuoles (Fig. 1a):
Small round to oval vacuoles located
in the neuropil (most vacuoles are not
larger than the nuclei of activated
astrocytes and neuronal cells)
Of kuru type (Fig. 1d):
Unicentric, rounded, amyloid
plaques with a saw-like contour
“Synaptic” pattern (Fig. 1g):
Diffuse or focal fine granular staining of the neuropil including
focal areas with more dense staining and immunoreactive dot-like
structures
Medium-sized vacuoles (Fig. 1b):
Small to medium-sized round to oval
vacuoles located in the neuropil (many
vacuoles are larger than the nuclei of
activated astrocytes and neuronal
cells)
Of florid type (Fig. 1e, f):
Large fibrillary amyloid
plaques surrounded by a halo
of spongiform change
Coarse or perivacuolar pattern (Fig. 1i, h):
Diffuse or patchy staining of the neuropil characterized by coarse
deposits (Fig. 1i) of irregular size and shape which are typically
(but not always) associated with clusters of large confluent
vacuoles (Fig. 1h). In the cerebellum (when present), these patchy/
coarse deposits are not associated with spongiform change and are
mostly found in the molecular layer (Fig. 1j)
Clusters of large, confluent vacuoles
(Fig. 1c):
Morula/grape-like clusters of
coalescing large vacuoles
Plaque-like pattern (Fig. 1k, l):
Focal, well-demarcated, rounded/oval extracellular deposits. In the
cerebellum they are mainly located in the granular layer.
Typically, some deposits are also found in the white matter. Their
size varies but at least some of them exceed the size of the nucleus
of cerebellar Purkinje cells. They are larger and more numerous in
MV 2K (Fig. 1k) than in VV2 (Fig. 1i)
Perineuronal pattern (Fig. 1m):
Dot-like pattern of staining outlining the contour of the perikarya
and/or the neurites of pyramidal neurons
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Table 4
Human prion disease types—terminology
No. Molecular types Histopathological types (Prion disease type with…..)
1 MM/MV 1 Diffuse synaptic deposits
2 VV2 Perineuronal and cerebellar plaque-like deposits
3 MV 2K Kuru plaques
4 MM 2C Cortical confluent vacuoles
5 MM 2T (=sFI) Thalamo-olivary atrophy
6 VV1 Corticostriatal synaptic deposits
7 MM 2V (=vCJD) Florid plaques
8 MM/MV 1+2C Mixed diffuse synaptic deposits and cortical confluent vacuoles
9 MV 2K+C Mixed Kuru plaques and cortical confluent vacuoles
10 Atypical
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